Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease

被引:27
|
作者
Koukias, Nikolaos
Buzzetti, Elena
Tsochatzis, Emmanuel A. [1 ,2 ]
机构
[1] Royal Free Hosp, UCL Inst Liver & Digest Hlth, Pond St, London NW3 2QG, England
[2] UCL, Pond St, London NW3 2QG, England
关键词
Non-alcoholic fatty liver disease; Fibrosis; Glucagon-like peptide 1; Leptin; Probiotics; INSULIN-RESISTANCE; METABOLIC SYNDROME; DOUBLE-BLIND; OBESITY; STEATOHEPATITIS; DYSBIOSIS; LIRAGLUTIDE; PATHWAYS; CAPACITY; CHILDREN;
D O I
10.23736/S0391-1977.16.02567-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and has a complex pathophysiology with multiple pathways of development and progression implicated. Intestinal hormones regulate multiple biological functions and may play a role in the pathogenesis of non alcoholic fatty liver disease (NAFLD) by affecting food intake, body weight and insulin resistance. Bacterial products can affect the secretion of these hormones and thus have an effect on metabolism. Gut microbiota are normally involved in the intestinal energy harvest and their role has been increasingly been implicated in the pathogenesis of obesity and NAFLD. The intestinal hormone pathways as well as the intestinal microbiota populations are potential therapeutic targets in the management of NAFLD. We review the evidence on the associations of the intestinal hormones and gut microbiota in the development, progression and treatment of NAFLD.
引用
收藏
页码:184 / 194
页数:11
相关论文
共 50 条
  • [31] Gut Dysfunction and Non-alcoholic Fatty Liver Disease
    Grabherr, Felix
    Grander, Christoph
    Effenberger, Maria
    Adolph, Timon Erik
    Tilg, Herbert
    FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [32] Role of Nutrition, Gene Polymorphism, and Gut Microbiota in Non-alcoholic Fatty Liver Disease
    Kong, Lingbo
    Lu, Yu
    Zhang, Siyu
    Nan, Yuemin
    Qiao, Liang
    DISCOVERY MEDICINE, 2017, 24 (131) : 95 - 106
  • [33] Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota
    Han, Ruiting
    Ma, Junli
    Li, Houkai
    FRONTIERS OF MEDICINE, 2018, 12 (06) : 645 - 657
  • [34] Modulation of the gut microbiota represents a new management for non-alcoholic fatty liver disease
    Bakhshimoghaddam, Farnush
    Alizadeh, Mohammad
    HEPATOBILIARY SURGERY AND NUTRITION, 2020, 9 (02) : 223 - 226
  • [35] Gut microbiota induced epigenetic modifications in the non-alcoholic fatty liver disease pathogenesis
    Tang, Ruiqi
    Liu, Rongrong
    Zha, Hua
    Cheng, Yiwen
    Ling, Zongxin
    Li, Lanjuan
    ENGINEERING IN LIFE SCIENCES, 2024, 24 (05):
  • [36] Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time?
    Demir, Muenevver
    Lang, Sonja
    Martin, Anna
    Farowski, Fedja
    Wisplinghoff, Hilmar
    Vehreschild, Maria J. G. T.
    Krawczyk, Marcin
    Nowag, Angela
    Scholz, Claus Jurgen
    Kretzschmar, Anne
    Roderburg, Christoph
    Lammert, Frank
    Goeser, Tobias
    Kasper, Philipp
    Steffen, Hans-Michael
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (11) : 1969 - 1977
  • [37] Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents
    Tokuhara, Daisuke
    FRONTIERS IN NUTRITION, 2021, 8
  • [38] Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie, Chencheng
    Halegoua-DeMarzio, Dina
    NUTRIENTS, 2019, 11 (11)
  • [39] Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota
    Ruiting Han
    Junli Ma
    Houkai Li
    Frontiers of Medicine, 2018, 12 : 645 - 657
  • [40] Gut Microbiota as an Emerging Therapeutic Avenue for the Treatment of Non-alcoholic Fatty Liver Disease
    Ralli, Tanya
    Neupane, Yub Raj
    Saifi, Zoya
    Kohli, Kanchan
    CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (46) : 4677 - 4685